Clinical pharmacology of current and future drugs for the acute treatment of migraine: a review and an update.
Migraine is a common disorder with a female prevalence of 17% and a male prevalence of 9%. Migraine is most often disabling and the patients need treatment of the attacks. The introduction of triptans has been a revolution for many migraine patients but only a minority of patients use these specific drugs. The pharmacokinetics and efficacy and tolerability of triptans are reviewed. The triptans can most likely with advantage be combined with NSAIDs and prokinetic drugs. Among future drugs, CGRP receptor antagonists are the most promising. These drugs have shown excellent tolerability with no more adverse events than placebo, but only one quarter of migraine patients have been pain-free after 2 hours in phase III studies. The development of current CGRP antagonists has been stopped.
Danish Headache Centre,University of Copenhagen, Department of Neurology, Glostrup Hospital, Glostrup, Denmark. ptha@glo.regionh.dk
Peer
P
Tfelt-Hansen
D000208:Acute Disease; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D015195:Drug Design; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014363:Tryptamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D017366:Serotonin Receptor Agonists; D014363:Tryptamines